

David Escors

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8535292/publications.pdf>

Version: 2024-02-01

107
papers

5,316
citations

76326

40
h-index

95266

68
g-index

123
all docs

123
docs citations

123
times ranked

8256
citing authors

#	ARTICLE	IF	CITATIONS
1	Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 107-119.	2.3	262
2	The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. <i>Nature Immunology</i> , 2014, 15, 965-972.	14.5	243
3	PD-1 co-stimulation contributes to ligand-induced T cell receptor downmodulation on CD8 ⁺ T cells. <i>EMBO Molecular Medicine</i> , 2011, 3, 581-592.	6.9	234
4	A sestrin-dependent Erk/Jnk/p38 MAPK activation complex inhibits immunity during aging. <i>Nature Immunology</i> , 2017, 18, 354-363.	14.5	223
5	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. <i>Cell Reports</i> , 2017, 20, 1818-1829.	6.4	220
6	Construction of a Severe Acute Respiratory Syndrome Coronavirus Infectious cDNA Clone and a Replicon To Study Coronavirus RNA Synthesis. <i>Journal of Virology</i> , 2006, 80, 10900-10906.	3.4	198
7	PD1 signal transduction pathways in T cells. <i>Oncotarget</i> , 2017, 8, 51936-51945.	1.8	191
8	The intracellular signalosome of PD-L1 in cancer cells. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 26.	17.1	174
9	The Membrane M Protein Carboxy Terminus Binds to Transmissible Gastroenteritis Coronavirus Core and Contributes to Core Stability. <i>Journal of Virology</i> , 2001, 75, 1312-1324.	3.4	162
10	Generation of a Replication-Competent, Propagation-Deficient Virus Vector Based on the Transmissible Gastroenteritis Coronavirus Genome. <i>Journal of Virology</i> , 2002, 76, 11518-11529.	3.4	145
11	Functional systemic CD4 immunity is required for clinical responses to PD-1/PD-L1 blockade therapy. <i>EMBO Molecular Medicine</i> , 2019, 11, e10293.	6.9	145
12	Role of non-classical MHC class I molecules in cancer immunosuppression. <i>Oncolmmunology</i> , 2013, 2, e26491.	4.6	131
13	HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7. <i>Journal of Virology</i> , 2010, 84, 5627-5636.	3.4	129
14	Targeting dendritic cell signaling to regulate the response to immunization. <i>Blood</i> , 2008, 111, 3050-3061.	1.4	119
15	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. <i>Oncotarget</i> , 2017, 8, 41932-41946.	1.8	95
16	Nonintegrating Lentivector Vaccines Stimulate Prolonged T-Cell and Antibody Responses and Are Effective in Tumor Therapy. <i>Journal of Virology</i> , 2009, 83, 3094-3103.	3.4	82
17	Effective cancer immunotherapy in mice by poly(I:C)-imiquimod complexes and engineered magnetic nanoparticles. <i>Biomaterials</i> , 2018, 170, 95-115.	11.4	81
18	Understanding LAG-3 Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5282.	4.1	78

#	ARTICLE	IF	CITATIONS
19	Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy. <i>New Journal of Science</i> , 2014, 2014, 1-25.	1.0	75
20	Construction of stable packaging cell lines for clinical lentiviral vector production. <i>Scientific Reports</i> , 2015, 5, 9021.	3.3	74
21	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. <i>Gene Therapy</i> , 2014, 21, 262-271.	4.5	73
22	Pseudaminic Acid on <i>Campylobacter jejuni</i> Flagella Modulates Dendritic Cell IL-10 Expression via Siglec-10 Receptor: A Novel Flagellin-Host Interaction. <i>Journal of Infectious Diseases</i> , 2014, 210, 1487-1498.	4.0	70
23	Organization of Two Transmissible Gastroenteritis Coronavirus Membrane Protein Topologies within the Virion and Core. <i>Journal of Virology</i> , 2001, 75, 12228-12240.	3.4	68
24	Transmissible Gastroenteritis Coronavirus Packaging Signal Is Located at the 5' End of the Virus Genome. <i>Journal of Virology</i> , 2003, 77, 7890-7902.	3.4	68
25	Intratumoral administration of mRNA encoding a fusokine consisting of IFN- γ and the ectodomain of the TGF- β receptor II potentiates antitumor immunity. <i>Oncotarget</i> , 2014, 5, 10100-10113.	1.8	66
26	Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 84-95.	6.7	62
27	A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. <i>Oncotarget</i> , 2014, 5, 7843-7857.	1.8	62
28	Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 328-343.	1.2	61
29	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. <i>Cancers</i> , 2020, 12, 344.	3.7	60
30	Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 12369-12382.	1.8	59
31	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1631.	4.1	59
32	A Novel Sorting Signal for Intracellular Localization Is Present in the S Protein of a Porcine Coronavirus but Absent from Severe Acute Respiratory Syndrome-associated Coronavirus. <i>Journal of Biological Chemistry</i> , 2004, 279, 43661-43666.	3.4	52
33	Phosphorylation and subcellular localization of transmissible gastroenteritis virus nucleocapsid protein in infected cells. <i>Journal of General Virology</i> , 2005, 86, 2255-2267.	2.9	52
34	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. <i>Oncotarget</i> , 2015, 6, 27160-27175.	1.8	51
35	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	7.2	51
36	Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. <i>Annals of Translational Medicine</i> , 2017, 5, 385-385.	1.7	50

#	ARTICLE	IF	CITATIONS
37	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2020, 11, 441.	3.5	48
38	Modulation of Regulatory T Cell Function by Monocyte-Derived Dendritic Cells Matured through Electroporation with mRNA Encoding CD40 Ligand, Constitutively Active TLR4, and CD70. <i>Journal of Immunology</i> , 2013, 191, 1976-1983.	0.8	47
39	Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2012, 12, 224-235.	0.5	45
40	PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. <i>OncImmunology</i> , 2012, 1, 86-88.	4.6	44
41	Cancer Immunotherapy of TLR4 Agonist- Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1. <i>Small</i> , 2019, 15, e1803993.	10.0	44
42	Coronavirus derived expression systems. <i>Journal of Biotechnology</i> , 2001, 88, 183-204.	3.8	40
43	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 586907.	4.8	40
44	Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. <i>Gene Therapy</i> , 2010, 17, 721-732.	4.5	38
45	Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using <i>ex vivo</i> myeloid-derived suppressor cells as a readout of therapeutic efficacy. <i>OncImmunology</i> , 2014, 3, e945378.	4.6	37
46	Clinical landscape of LAG-3-targeted therapy. <i>Immuno-Oncology Technology</i> , 2022, 14, 100079.	0.3	37
47	Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 113-123.	2.3	36
48	Membrane cell fusion activity of the vaccinia virus A17/A27 protein complex. <i>Cellular Microbiology</i> , 2007, 10, 070816180854001-???	2.1	34
49	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. <i>Oncotarget</i> , 0, 7, 42698-42715.	1.8	34
50	Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications. <i>Cancers</i> , 2013, 5, 815-837.	3.7	33
51	Conventional Dendritic Cells Are Required for the Activation of Helper-Dependent CD8 T Cell Responses to a Model Antigen After Cutaneous Vaccination with Lentiviral Vectors. <i>Journal of Immunology</i> , 2011, 186, 4565-4572.	0.8	32
52	CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. <i>Oncotarget</i> , 2017, 8, 15789-15801.	1.8	32
53	Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. <i>Journal of Gene Medicine</i> , 2007, 9, 67-76.	2.8	30
54	Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance. <i>Scientifica</i> , 2012, 2012, 1-14.	1.7	30

#	ARTICLE	IF	CITATIONS
55	Signaling Mechanisms that Balance Anti-viral, Auto-reactive, and Antitumor Potential of Low Affinity T Cells. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 01, .	1.5	29
56	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2411.	4.1	28
57	Assessing T-cell responses in anticancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e26148.	4.6	27
58	Drafting the proteome landscape of myeloid-derived suppressor cells. <i>Proteomics</i> , 2016, 16, 367-378.	2.2	26
59	Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 29-39.	1.7	23
60	Distinct Activation Mechanisms of NF- κ B Regulator Inhibitor of NF- κ B Kinase (IKK) by Isoforms of the Cell Death Regulator Cellular FLICE-like Inhibitory Protein (cFLIP). <i>Journal of Biological Chemistry</i> , 2016, 291, 7608-7620.	3.4	23
61	EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. <i>Oncotarget</i> , 2015, 6, 368-380.	1.8	23
62	Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. <i>Cancers</i> , 2019, 11, 808.	3.7	22
63	Characterization of Macrophage Endogenous <i>S</i> -Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO ₂ Chromatography. <i>Journal of Proteome Research</i> , 2018, 17, 1172-1182.	3.7	21
64	Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. <i>Oncotarget</i> , 2015, 6, 23944-23958.	1.8	21
65	Immune modulation by genetic modification of dendritic cells with lentiviral vectors. <i>Virus Research</i> , 2013, 176, 1-15.	2.2	20
66	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. <i>Molecular Therapy</i> , 2018, 26, 2553-2566.	8.2	20
67	Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. <i>Mucosal Immunology</i> , 2014, 7, 89-100.	6.0	19
68	Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapy. <i>EMBO Molecular Medicine</i> , 2020, 12, e12706.	6.9	19
69	Kaposi's Sarcoma-Associated Herpesvirus vFLIP and Human T Cell Lymphotropic Virus Type 1 Tax Oncogenic Proteins Activate I κ B Kinase Subunit β by Different Mechanisms Independent of the Physiological Cytokine-Induced Pathways. <i>Journal of Virology</i> , 2011, 85, 7444-7448.	3.4	15
70	Novel function for the p38 α /MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10. <i>International Journal of Cancer</i> , 2014, 134, 575-586.	5.1	15
71	PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5918.	4.1	15
72	Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix. <i>Pathology International</i> , 2015, 65, 476-485.	1.3	14

#	ARTICLE	IF	CITATIONS
73	The transduction pattern of IL12 α -encoding lentiviral vectors shapes the immunological outcome. <i>European Journal of Immunology</i> , 2015, 45, 3351-3361.	2.9	14
74	Targeting Lentiviral Vectors for Cancer Immunotherapy. <i>Current Cancer Therapy Reviews</i> , 2011, 7, 248-260.	0.3	13
75	DNA fusion vaccine designs to induce tumor-lytic CD8 $^{+}$ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1. <i>International Journal of Cancer</i> , 2013, 133, 1400-1407.	5.1	13
76	Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 51-59.	2.8	13
77	On the Mechanism of T cell receptor downmodulation and its physiological significance. <i>The Journal of Bioscience and Medicine</i> , 0, , 1-6.	0.4	12
78	Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. <i>Gene Therapy</i> , 2017, 24, 370-375.	4.5	11
79	The Membrane M Protein of the Transmissible Gastroenteritis Coronavirus Binds to the Internal Core through the Carboxy-Terminus. <i>Advances in Experimental Medicine and Biology</i> , 2001, 494, 589-593.	1.6	11
80	TNF- α -Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 811867.	4.8	11
81	Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. <i>Cancers</i> , 2020, 12, 2181.	3.7	9
82	On the Mechanism of T cell receptor down-modulation and its physiological significance. <i>The Journal of Bioscience and Medicine</i> , 2011, 1, .	0.4	9
83	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. <i>British Journal of Cancer</i> , 2022, 126, 1168-1177.	6.4	9
84	Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity. <i>Molecular Therapy</i> , 2017, 25, 504-511.	8.2	8
85	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	2.4	8
86	Nature of the Virus Associated with Endemic Balkan Nephropathy. <i>Emerging Infectious Diseases</i> , 2002, 8, 869-870.	4.3	7
87	Immunopurification applied to the study of virus protein composition and encapsidation. <i>Journal of Virological Methods</i> , 2004, 119, 57-64.	2.1	7
88	Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48.	0.5	7
89	Radiopotential of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 221-226.	0.6	6
90	A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets. <i>Journal of Personalized Medicine</i> , 2021, 11, 542.	2.5	6

#	ARTICLE	IF	CITATIONS
91	Impact of T cell selection methods in the success of clinical adoptive immunotherapy. Cellular and Molecular Life Sciences, 2014, 71, 1211-1224.	5.4	5
92	Novel immunotherapies for the treatment of melanoma. Immunotherapy, 2016, 8, 613-632.	2.0	5
93	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. , 2014, , .		4
94	Targeted Lentiviral Vectors: Current Applications and Future Potential. , 0, , .		3
95	Constraints on General Relativity Geodesics by a Covariant Geometric Uncertainty Principle. Physics, 2021, 3, 790-798.	1.4	2
96	Lentiviral expression of GAD67 and CCK promoter-driven opsins to target interneurons in vitro and in vivo. Journal of Gene Medicine, 2016, 18, 27-37.	2.8	1
97	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. Lung Cancer Management, 2018, 7, LMT07.	1.5	1
98	Clinical Grade Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 69-85.	0.3	1
99	Covariant Space-Time Line Elements in the Friedmann-Lemaître-Robertson-Walker Geometry. Axioms, 2022, 11, 310.	1.9	1
100	Lentiviral Vectors in Immunotherapy. , 0, , .		0
101	Ex Vivo MDSC Differentiation Models. SpringerBriefs in Immunology, 2016, , 49-59.	0.1	0
102	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 390-390.	1.7	0
103	Immunomodulation by Genetic Modification Using Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 51-67.	0.3	0
104	Development of Retroviral and Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 11-28.	0.3	0
105	Cell and Tissue Gene Targeting with Lentiviral Vectors. SpringerBriefs in Biochemistry and Molecular Biology, 2012, , 29-50.	0.3	0
106	Differentiation of Murine Myeloid-Derived Suppressor Cells. SpringerBriefs in Immunology, 2016, , 25-37.	0.1	0
107	Editorial on "CTLA-4 is a haploinsufficient suppressor of T cell lymphomagenesis". Translational Cancer Research, 2018, 7, S58-S60.	1.0	0